Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan-based Teijin Pharma and Pulmagen Therapeutics have signed an exclusive licensing agreement granting Teijin Pharma the rights to develop, manufacture and market ADC3680, a bronchial asthma therapeutic discovered by Pulmagen Therapeutics, in Japan.
Subscribe to our email newsletter
Teijin Pharma is planning to begin phase I clinical trials for ADC3680 in Japan in April 2013, while Pulmagen Therapeutics has already begun phase II clinical trials for the same drug in the UK.
ADC3680 uses anti-inflammatory mechanism to inhibit the binding of an inflammatory mediator, PGD2 to its receptor, CRTh2 to reduce pulmonary inflammation and improve overall asthma control.
The drug is an oral agent, which can be used both as a monotherapy or in combination with other established drugs including inhaled corticosteroids.
It can also be used to treat respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease and allergic rhinitis and certain non-respiratory inflammatory diseases.